VEA
FULC icon

Virtus ETF Advisers’s Fulcrum Therapeutics FULC Stock Holding History

Virtus ETF Advisers’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11,813
Closed -$42.2K – 481
2024
Q3 		$42.2K Buy
11,813
+207
+2% +$1.54K 0.02% 445
2024
Q2 		$72K Buy
+11,606
New +$87.9K 0.04% 428
2022
Q2 		– Sell
-9,496
Closed -$225K – 456
2022
Q1 		$225K Sell
9,496
-563
-6% -$7.97K 0.1% 191
2021
Q4 		$178K Buy
+10,059
New +$199K 0.07% 254

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Virtus ETF Advisers's FULC Position: Q4 2024 in Review

Virtus ETF Advisers sold out of Fulcrum Therapeutics (FULC) in Q4 2024, closing a stake of 11,813 shares — an estimated $42.2K sold.

Virtus ETF Advisers first reported a position in FULC in Q4 2021 and held it in 4 quarters. The position peaked at $225K in Q1 2022. 119 funds tracked by Wall St. Rank hold FULC as of Q4 2024.

  • Virtus ETF Advisers reported no remaining Fulcrum Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Virtus ETF Advisers sold 11,813 Fulcrum Therapeutics shares in Q4 2024, an estimated $42.2K.
  • Virtus ETF Advisers first reported a position in Fulcrum Therapeutics in Q4 2021 and held it in 4 quarters.
  • Virtus ETF Advisers's Fulcrum Therapeutics position peaked at $225K in Q1 2022.
  • 119 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q4 2024.

Based on Virtus ETF Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.